Skip to main content

Table 3 Results throughout the follow-up

From: Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain

 

N

Visual acuity mean ± SD/median

Change in thickness mean ± SD

Number of visits mean ± SD

Number of injections mean ± SD

Initial

314

O.8 (20/125) ± 0.5/0.7

   

3 months

314

0.7(20/100) ± 0.5/0.6

−0.35 ± 0.35

2.7 ± 0.8

2.6 ± 0.5

1st year

314

0.8(20/125) ± 0.5/0.7

−0.32 ± 0.4

7.3 ± 2.1

3.9 ± 1.5

2nd year

314

1(20/200) ± 0.6/0.8

−0.3 ± 0.4

5.2 ± 2.7

1.1 ± 1.5

3rd year

229

1(20/200) ± 0.6/1

−0.3 ± 0.4

3.9 ± 2.3

1.5 ± 2.4

4th year

109

1.1(20/250) ± 0.6/1

−0.31 ± 0.4

3.6 ± 2.2

1.8 ± 3.1

Final/total

314

1.1(20/250) ± 0.6/1

−0.33 ± 0.4

17.7 ± 7.6

6.8 ± 5,1

  1. N number, SD Standard Deviation.